Therapeutic interventions for hypertension in metabolic syndrome: a comprehensive approach

References

• Lorenzo C, Okoloise M, Williams K, Stern MP, Haffner SM. San Antonio Heart Study. The metabolic syndrome as predictor of type 2 diabetes: the San Antonio heart study. Diabetes Care26(11), 3153–3159 (2003).
   PubMed Web of Science ®Google Scholar
• Palaniappan L, Carnethon MR, Wang Y et al. Insulin Resistance Atherosclerosis Study. Predictors of the incident metabolic syndrome in adults: the Insulin Resistance Atherosclerosis Study. Diabetes Care27(3), 788–793 (2004).
   PubMed Web of Science ®Google Scholar
• Eckel RH, Grundy SM, Zimmet PA. The metabolic syndrome. Lancet365, 1415–1428 (2005).
   PubMed Web of Science ®Google Scholar
• Isomaa B, Almgren P, Tuomi T et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care24, 683–689 (2001).
   PubMed Web of Science ®Google Scholar
• Lakka HM, Laaksonen DE, Lakka TA et al. The metabolic syndrome and total and cardiovascular disease mortality in middle aged men. JAMA288, 2709–2716 (2002).
   PubMed Web of Science ®Google Scholar
• Girman CJ, Rhodes T, Mercuri M et al. The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Am. J. Cardiol.93, 136–141 (2004).
   PubMed Web of Science ®Google Scholar
• Malik S, Wong ND, Franklin SS et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation110, 1245–1250 (2004).
   PubMed Web of Science ®Google Scholar
• Chobanian AV, Bakris GL, Black HR et al. National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee: the seventh report of the joint national committee on prevention, detection, evaluation and treatment of high blood pressure: the JNC 7 report. JAMA289(19), 2560–2571 (2003).
   PubMed Web of Science ®Google Scholar
• McFarlane SI, Sica DA, Sowers JR. Stroke in patients with diabetes and hypertension. J. Clin. Hypertens. (Greenwich)7(5), 286–292 (2005).
   PubMedGoogle Scholar
• Reaven GM, Lithell H, Landsberg L. Hypertension and associated metabolic abnormalities – the role of insulin resistance and the sympathoadrenal system. N. Engl. J. Med.334, 374–381 (1996).
   PubMed Web of Science ®Google Scholar
• Sowers JR, Epstein M, Diabetes mellitus and associated hypertension, vascular disease, and nephropathy: an update. Hypertension26, 869–879 (1995).
   PubMed Web of Science ®Google Scholar
• Grunfeld B, Balzareti M, Romo M, Gimenez M, Gutman R. Hyperinsulinemia in normotensive offspring of hypertensive parents. Hypertension23(Suppl. 1), I12–I15 (1994).
   Google Scholar
• Steinberg HO, Chaker H, Leaming R, Johnson A, Brechtel G, Baron AD. Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J. Clin. Invest.97, 2601–2610 (1996).
   PubMed Web of Science ®Google Scholar
• Sowers JR, Epstein M, Frolich ED. Diabetes, hypertension and cardiovascular disease: an update. Hypertension37, 1053–1059 (2001).
   PubMed Web of Science ®Google Scholar
• El-Atat F, Aneja A, Mcfarlane S, Sowers J. Obesity and hypertension. Endocrinol. Metab. Clin. North Am.32, 823–854 (2003).
   PubMedGoogle Scholar
• Sowers JR. Insulin resistance and hypertension. Am. J. Physiol. Heart Circ. Physiol.286, H1597–H1602 (2004).
   PubMed Web of Science ®Google Scholar
• Castro JP, El-Atat FA, McFarlane SI, Aneja A, Sowers JR. Cardiometabolic syndrome: pathophysiology and treatment. Curr. Hypertens. Rep.5, 393–401 (2003).
   PubMed Web of Science ®Google Scholar
• Troisi RJ, Weiss ST, Parker DR, Sparrow D, Young JB, Landsberg L. Relation of obesity and diet to sympathetic nervous system activity. Hypertension17, 669–677 (2001).
   Google Scholar
• Tuck ML, Sowers J, Dornfield L, Kledzik G, Maxwell M. The effect of weight reduction on blood pressure plasma renin activity and plasma aldosterone level in obese patients. N. Engl. J. Med.304, 930–933 (1981).
   PubMed Web of Science ®Google Scholar
• Hall JE, Crook ED, Jones DW, Wofford MR, Dubbert PM. Mechanisms of obesity-associated cardiovascular and renal disease. Am. J. Med. Sci.324, 127–137 (2002).
   PubMed Web of Science ®Google Scholar
• Weyer C, Pratley RE, Snitker Spraul M, Ravussin E, Tataranni PA. Ethnic differences in insulinemia and sympathetic tone as links between obesity and blood pressure. Hypertension36, 531–537 (2000).
   PubMedGoogle Scholar
• Landsberg L, Young JB. Insulin-mediated glucose metabolism in the relationship between dietary intake and sympathetic nervous system activity. Int. J. Obes.9(Suppl. 2), 63–68 (1985).
   PubMed Web of Science ®Google Scholar
• McFarlane SI, Banerji M, Sowers JR. Insulin resistance and cardiovascular disease. J. Clin. Endocrinol. Metab.86, 713–718 (2001).
   PubMed Web of Science ®Google Scholar
• Zhang R, Reisin E. Obesity-hypertension; the effects on cardiovascular and renal systems. Am. J. Hypertens.13, 1308–1314 (2000).
   PubMed Web of Science ®Google Scholar
• Hansson L, Lindholm LH, Niskanen L et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the CaptoPril Prevention Project (CAPPP) randomized trial. Lancet353, 611–616 (1999).
   PubMed Web of Science ®Google Scholar
• Yusuf S, Gerstein H, Hoogwerf, B et al. Ramipril and the development of diabetes. JAMA286, 1882–1885 (2001).
   PubMed Web of Science ®Google Scholar
• Lindholm LH, Ibsen H, Borch-Johnsen K et al. Risk of new-onset diabetes in the Losartan Intervention for Endpoint Reduction in Hypertension study. J. Hypertens.20, 1879–1886 (2002).
   PubMed Web of Science ®Google Scholar
• The DREAM trial investigators. Effect of ramipril on the incidence of diabetes. N. Engl. J. Med.355, 1551–1562 (2006).
   PubMed Web of Science ®Google Scholar
• Henriksen EJ, Jacob S, Kinnick TR, Teachey MK, Krekler M. Selective angiotensin II receptor antagonism reduces insulin resistance in obese Zucker rats. Hypertension38, 884–890 (2001).
   PubMed Web of Science ®Google Scholar
• El-Atat F, McFarlane SI, Sowers JR. Diabetes, hypertension, and cardiovascular derangements: pathophysiology and management. Curr. Hypertens. Rep.6(3), 215–223 (2004).
   PubMed Web of Science ®Google Scholar
• McFarlane SI, Kumar A, Sowers JR. Mechanisms by which angiotensin-converting enzyme inhibitors prevent diabetes and cardiovascular disease. Am. J. Cardiol.91, 30H–37H (2003).
   PubMed Web of Science ®Google Scholar
• Schupp M, Janke J, Clasen R, Unger T, Kintscher U. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-γ activity. Circulation109, 2054–2057 (2004).
   PubMed Web of Science ®Google Scholar
• Weiss R, Dufour S, Taksali SE et al. Prediabetes in obese youth: a syndrome of impaired glucose tolerance, severe insulin resistance, and altered myocellular and abdominal fat partitioning. Lancet362, 951–957 (2003).
   PubMed Web of Science ®Google Scholar
• Bloomgarden ZT. Second World Congress on the insulin resistance syndrome: hypertension, cardiovascular disease, and treatment approaches. Diabetes Care.28(8), 2073–2080 (2005).
   PubMedGoogle Scholar
• Sharma AM, Janke J, Gorzelniak K, Engeli S, Luft FC. Angiotensin blockade prevents type 2 diabetes by formation of fat cells. Hypertension40, 609–611 (2002).
   PubMed Web of Science ®Google Scholar
• Furuhashi M, Ura N, Takizawa H et al. Blockade of the renin-angiotensin system decreases adipocyte size with improvement in insulin sensitivity. J. Hypertens.22, 1977–1982 (2004).
   PubMed Web of Science ®Google Scholar
• Garrison RJ, Kannel WB, Stokes J, Castelli WP. Incidence and precursors of hypertension in young adults: the Framingham Offspring Study. Prev. Med.16, 234–251 (1987).
   Web of Science ®Google Scholar
• Lennie TA, Chung ML, Habash DL, Moser DK. Dietary fat intake and proinflammatory cytokine levels in patients with heart failure. J. Card. Fail.11(8), 613–618 (2005).
   PubMedGoogle Scholar
• Pai JK, Pischon T, Ma J et al. Inflammatory markers and the risk of coronary heart disease in men and women. N. Engl. J. Med.351(25), 2599–2610 (2004).
   PubMed Web of Science ®Google Scholar
• Sarzani R, Dessi-Fulgheri P, Salvi F et al. A novel promoter variant of the natriuretic peptide clearance receptor gene is associated with lower atrial natriuretic peptide and higher blood pressure in obese hypertensives. J. Hypertens.17, 1301–1305 (1999).
   PubMed Web of Science ®Google Scholar
• McFarlane SI, Sowers JR. Cardiovascular endocrinology 1: aldosterone function in diabetes mellitus: effects on cardiovascular and renal disease. J. Clin. Endocrinol. Metab.88, 516–523 (2003).
   PubMed Web of Science ®Google Scholar
• Nannipieri M, Seghieri G, Catalano C, Prontera T, Baldi S, Ferrannini E. Defective regulation and action of atrial natriuretic peptide in type 2 diabetes. Horm. Metab. Res.34, 265–270 (2002).
   PubMedGoogle Scholar
• Vettor R, Mazzonetto P, Macor C et al. Effect of endogenous organic hyperinsulinemia on blood pressure and serum triglycerides. Eur. J. Clin. Invest.24, 350–354 (1994).
   PubMedGoogle Scholar
• Hall JE, Brands MW, Mizelle HL, Gaillard CA, Hildebrandt DA. Chronic intrarenal hyperinsulinemia does not cause hypertension. Am. J. Physiol.260, F663–F669 (1991).
   PubMed Web of Science ®Google Scholar
• Alexander CM, Landsman PB, Teutsch SM, Haffner SM. NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes52, 1210–1214 (2003).
   PubMed Web of Science ®Google Scholar
• Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA287(3), 356–359 (2002).
   PubMed Web of Science ®Google Scholar
• Olshansky SJ, Passaro DJ, Hershow RC et al. A potential decline in life expectancy in the United States in the 21st Century. N. Engl. J. Med.352, 1138–1145 (2005).
   PubMed Web of Science ®Google Scholar
• Knowler WC, Barrett-Connor E, Fowler SE et al. Reduction in the incidence of Type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med.346, 393–403 (2002).
   PubMed Web of Science ®Google Scholar
• Sacks FM, Svetkey LP, Vollmer WM et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet: DASH-Sodium Collaborative Research Group. N. Engl. J. Med.344, 3–10 (2001).
   PubMed Web of Science ®Google Scholar
• Obarzanek E, Sacks FM, Vollmer WM et al. For the DASH Research Group. Effects on blood lipids of a blood pressure lowering diet: the Dietary Approaches to Stop Hypertension (DASH) Trial. Am. J. Clin. Nutr.74, 80–89 (2001).
   PubMed Web of Science ®Google Scholar
• Bakris GL, Williams M, Dworkin L et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach: National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am. J. Kidney Dis.36, 646–661 (2000).
   PubMed Web of Science ®Google Scholar
• Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care16, 434–444 (1993).
   PubMed Web of Science ®Google Scholar
• Hebert PR, Moser M, Mayer J, Glynn RJ, Hennekens CH. Recent evidence on drug therapy of mild to moderate hypertension and decreased risk of coronary heart disease. Arch. Intern. Med.153, 578–581 (1993).
   PubMed Web of Science ®Google Scholar
• Moser M, Hebert PR. Prevention of disease progression, left ventricular hypertrophy and congestive heart failure in hypertension treatment trials. J. Am. Coll. Cardiol.27, 1214–1218 (1996).
   PubMed Web of Science ®Google Scholar
• Psaty BM, Smith NL, Siscovick DS et al. Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis. JAMA277, 739–745 (1997).
   PubMed Web of Science ®Google Scholar
• Staessen JA, Fagard R, Thijs L et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet350, 757–764 (1997).
   PubMed Web of Science ®Google Scholar
• SHEP Cooperative Research Group, Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA265, 3255–3264 (1991).
   PubMed Web of Science ®Google Scholar
• Yusuf S, Sleight P, Pogue J et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N. Engl. J. Med.342, 145–153 (2000).
   PubMed Web of Science ®Google Scholar
• Dahlof B, Devereux RB, Kjeldsen SE et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet359, 995–1003 (2002).
   PubMed Web of Science ®Google Scholar
• Hansson L, Zanchetti A, Carruthers SG et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet351, 1755–1762 (1998).
   PubMed Web of Science ®Google Scholar
• The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. JAMA.288, 2981–2997 (2002).
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in Type 2 diabetes: UKPDS 39. Br. Med. J.317, 713–720 (1998).
   PubMed Web of Science ®Google Scholar
• Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy: The Collaborative Study Group. N. Engl. J. Med.329, 1456–1462 (1993).
   PubMed Web of Science ®Google Scholar
• Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with Type 2 diabetes and nephropathy. N. Engl. J. Med.345, 861–869 (2001).
   PubMed Web of Science ®Google Scholar
• Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to Type 2 diabetes. N. Engl. J. Med.345, 851–860 (2001).
   PubMed Web of Science ®Google Scholar
• Sowers JR, Reed J. Clinical advisory treatment of hypertension in diabetes. J. Clin. Hypertens.2, 132–133 (2000).
   Google Scholar
• Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet355, 253–259 (2000).
   PubMed Web of Science ®Google Scholar
• Lindholm LH, Ibsen H, Dahlof B et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet359, 1004–1010 (2002).
   PubMed Web of Science ®Google Scholar
• Lindholm LH, Ibsen H, Borch-Johnsen K et al. Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. J. Hypertens.20, 1879–1886 (2002).
   PubMed Web of Science ®Google Scholar
• The DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet368, 1096–1105 (2006).
   PubMed Web of Science ®Google Scholar
• Wing LMH, Reid CM, Ryan P et al, for Second Australian National Blood Pressure Study Group. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N. Engl. J. Med.348, 583–592 (2003).
   PubMed Web of Science ®Google Scholar
• Pyorala K, Ballantyne CM, Gumbiner B et al. The Scandinavian Simvastatin Survival Study (4S): reduction of cardiovascular events by simvastatin in nondiabetic coronary heart disease patients with and without the metabolic syndrome: subgroup analyses of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care27, 1735–1740 (2004).
   PubMed Web of Science ®Google Scholar
• Armitage J, Collins R. Need for large scale randomised evidence about lowering LDL cholesterol in people with diabetes mellitus: MRC/BHF heart protection study and other major trials MRC/BHF Heart Protection Study. Heart84(4), 357–360 (2000).
   PubMedGoogle Scholar